Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.

Radiat Oncol · 2014 · PMC3922961 · PMID 24479954

Europe PMC DOI

hedged sentences

0.2560

closest p · 5.1× alpha

0.2560

boldest claim

The sentences

did not achieve significancep = .256not close (p > 0.1)

SUV with a cutoff value of 5 predicted for OS and PFS (p = .024 for each) but did not achieve significance for LC (p = .256).

also in 1,397 other papers

failed to achieve significanceno p-value reported

In the two studies which investigated SUV max as a prognostic factor for the treatment of early-stage NSCLC with SBRT and failed to achieve significance, both cite sample size as a possible contributor to the lack of findings [ 9 , 10 ].

also in 299 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.